Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer (2010) 2.90

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med (2008) 2.47

The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men. Eur Urol (2014) 1.57

Tumor markers in prostate cancer I: blood-based markers. Acta Oncol (2011) 1.28

A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomarkers Prev (2010) 1.12

Overdiagnosis of prostate cancer. J Natl Cancer Inst Monogr (2012) 1.11

First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts. Nucl Med Biol (2013) 0.87

Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer. Curr Opin Urol (2009) 0.85

Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer. BJU Int (2010) 0.82

Circulating biomarkers for prostate cancer. World J Urol (2007) 0.82

Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses. Clin Chem Lab Med (2012) 0.78

New Prognostic Markers: The Pathway from Research to Clinical Practice. Grand rounds Urol (2009) 0.75

Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94

Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61

Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91

Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology (2010) 14.07

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol (2010) 12.64

Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol (2006) 8.61

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26

Variations in morbidity after radical prostatectomy. N Engl J Med (2002) 7.26

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol (2003) 6.93

The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst (2007) 6.12

NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw (2010) 5.98

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst (2011) 5.73

Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 5.36

Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol (2007) 5.24

Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23

A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol (2003) 5.20

Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst (2008) 5.09

Variations in lung cancer risk among smokers. J Natl Cancer Inst (2003) 5.00

Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2005) 4.89

Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). Urology (2005) 4.71

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ (2010) 4.42

Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37

Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. J Clin Virol (2008) 4.25

Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol (2010) 4.15

Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst (2006) 4.14

Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med (2010) 4.11

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10

Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol (2006) 4.05

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol (2008) 4.02

Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93

Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol (2002) 3.93

Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol (2010) 3.76

Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74

Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst (2007) 3.70

Against diagnosis. Ann Intern Med (2008) 3.69

Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol (2013) 3.65

Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol (2002) 3.61

Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 3.53

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ (2013) 3.51

Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol (2008) 3.50

Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol (2006) 3.46

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol (2009) 3.42

Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol (2013) 3.41

Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36

Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol (2003) 3.27

Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol (2009) 3.24

Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg (2006) 3.23

Comparative effectiveness of prostate cancer surgical treatments: a population based analysis of postoperative outcomes. J Urol (2010) 3.18

Contemporary open and robotic radical prostatectomy practice patterns among urologists in the United States. J Urol (2012) 3.12

Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell (2013) 3.08

Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer (2008) 3.06

Using relative utility curves to evaluate risk prediction. J R Stat Soc Ser A Stat Soc (2009) 3.04

Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer (2011) 3.02

Acupuncture for migraine prophylaxis. Cochrane Database Syst Rev (2009) 3.00

The prevention of prostate cancer--the dilemma continues. N Engl J Med (2003) 3.00

Variations among high volume surgeons in the rate of complications after radical prostatectomy: further evidence that technique matters. J Urol (2005) 2.98

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer (2010) 2.90

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res (2010) 2.87

The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87